Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review.
BACKGROUND
Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the treatment of chronic hepatitis B.


RESULTS
To evaluate the comparison of the efficacy of LAM and LdT in the treatment of chronic hepatitis B by a systematic review and meta-analysis of clinical trials, we searched PUBMED (from 1990 to April 2010), Web of Science (from 1990 to April 2010), EMBASE (from 1990 to April 2010), CNKI (National Knowledge Infrastructure) (from 1990 to April 2010), VIP database (from 1990 to April 2010), WANFANG database (from 1990 to April 2010), the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. At the end of one-year treatment, LdT was better than LAM at the biochemical response, virological response, HBeAg loss, therapeutic response, while less than at the viral breakthrough and viral resistance, but there was no significant difference in the HBeAg seroconversion and HBsAg response. LdT was better than LAM at the HBeAg seroconversion with prolonged treatment to two years.


CONCLUSIONS
In summary, LdT was superior in inhibiting HBV replication and preventing drug resistance as compared to LAM for CHB patients. But LdT may cause more nonspecific adverse events and can lead to more CK elevation than LAM. It is thus recommended that the LdT could be used as an option for patients but adverse events, for example CK elevation, must be monitored.
Zhao
Shushan
S
Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China. zhaoshuiquan@gmail.com
Tang
Lanhua
L
Fan
Xuegong
X
Chen
Lizhang
L
Zhou
Rongrong
R
Dai
Xiahong
X
D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016208:Databases, Factual; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D009705:Nucleosides / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D016896:Treatment Outcome
D000998:Antiviral Agents; D009705:Nucleosides; D011744:Pyrimidinones; D000077712:Telbivudine; D019259:Lamivudine; D013936:Thymidine
Stat Med. 2010 Jan 15;29(1):1-13
19844944
J Clin Epidemiol. 2000 Feb;53(2):207-16
10729693
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
BMJ. 2001 Jul 7;323(7303):42-6
11440947
Hepatology. 2008 Feb;47(2):447-54
18080339
J Hepatol. 2006 Oct;45(4):529-38
16879891
Antimicrob Agents Chemother. 2001 Jan;45(1):229-35
11120971
Lancet. 1997 Aug 2;350(9074):326-9
9251637
Gastroenterology. 2009 Feb;136(2):486-95
19027013
Gastroenterology. 2005 Aug;129(2):528-36
16083710
J Hepatol. 2009 Aug;51(2):403-10
19467727
N Engl J Med. 2004 Dec 30;351(27):2832-8
15625334
N Engl J Med. 2007 Dec 20;357(25):2576-88
18094378
Hepatogastroenterology. 2007 Mar;54(74):545-8
17523319
J Viral Hepat. 2004 Mar;11(2):97-107
14996343
Adv Ther. 2009 Feb;26(2):155-69
19225726